Summary
Boston Scientific Corporation (BSX) filed an 8-K on December 20, 2004, primarily to announce a key executive appointment. The Board of Directors appointed Paul A. LaViolette as the new Chief Operating Officer (COO) of the company, effective December 14, 2004. Mr. LaViolette has an extensive history within Boston Scientific, having held various leadership roles in international and divisional operations since joining in 1994, most recently as Senior Vice President and Group President for the Cardiovascular businesses. This appointment signals a significant internal promotion and likely reflects the company's confidence in Mr. LaViolette's experience to oversee operational functions. The filing also mentions that additional management promotions were announced, detailed in an accompanying press release. Investors should note the details surrounding a home improvement loan previously provided to Mr. LaViolette, which is due in October 2005, as well as the standard provision of retention and indemnification agreements for executive officers.
Key Highlights
- 1Appointment of Paul A. LaViolette as Chief Operating Officer (COO) effective December 14, 2004.
- 2Mr. LaViolette has a long tenure with Boston Scientific, holding various senior leadership positions since 1994.
- 3The company announced additional management promotions alongside the COO appointment.
- 4Details provided on a $400,000 home improvement loan to Mr. LaViolette, with principal and interest due in October 2005.
- 5The filing confirms the standard provision of retention and indemnification agreements for executive officers.